Matthias Verbesselt

Matthias Verbesselt

Auto-generated profile, based on publicly available information

Matthias Verbesselt

Cardiovascular Center Aalst, OLV Clinic Aalst , Moorselbaan 164, 9300 Aalst , Belgium

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2022 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
MVMatthias Verbesselt
Matthias Verbesselt
EMEvelyne Meekers
Evelyne Meekers
PVPeter Vandenberghe
Peter Vandenberghe
MDMichel Delforge
Michel Delforge
CVChristophe Vandenbriele
Christophe Vandenbriele
Background: Drug-induced myocarditis is a rare complication of certain cancer treatments, characterized by the development of myocardial inflammation shortly after initiation of treatment, potentially leading to heart failure and/or malignant arrhythmias. The development of eosinophilic myocarditis after administration of lenalidomide has been described and bortezomib has been associated with the development of cardiomyopathies and atherosclerosis.Case summary: A 69-year-old woman, recently diagnosed with multiple myeloma underwent local radiotherapy for a pathological fracture of the 4th lumbar vertebra and was treated with bortezomib–lenalidomide–dexamethasone. Within 19 days after therapy initiation, she presented with gastrointestinal symptoms, an erythematous pruritic rash, and general fatigue. Surprisingly, routine electrocardiogram (ECG) showed upwardly concave ST-elevation in I and aVL and ST-depressions in II, III, and aVF. Troponin levels were markedly elevated to 5470 ng/L. Complete blood count revealed eosinophilia. Based on further cardiac work-up, including echocardiography, coronary angiography, and cardiac magnetic resonance imaging (MRI) showing positive T2 imaging and patchy subepicardial late gadolinium enhancement, she was diagnosed with hypersensitivity myocarditis. Additional endomyocardial heart biopsy did not reveal any abnormalities, probably due to sampling error. After discontinuation of chemotherapy and prompt treatment with high doses of corticosteroids, the patient recovered.Discussion: Diagnosis of drug-induced myocarditis can be challenging and even long known widely used (chemo)therapy should be considered a potential trigger. Early diagnosis and treatment are crucial, warranting alertness for suggestive symptoms. Cardiac biomarkers, ECG monitoring, and cardiac MRI are key to confirm the diagnosis. In patients with preserved left ventricular systolic function, two-dimensional speckle tracking echocardiography can provide additional diagnostic information. Every patient presenting with eosinophilia and/or acute onset of auto-immune symptoms after initiation of therapy with lenalidomide/bortezomib deserves prompt cardiac screening. The gold standard remains an endomyocardial biopsy, although sampling error may occur.

17 February 2022 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
SCSarah Cappuyns
Sarah Cappuyns
MVMatthias Verbesselt
Matthias Verbesselt
ABAlexander Van De Bruaene
Alexander Van De Bruaene
BJBogaert Jan
Bogaert Jan
LMLucienne Michaux
Lucienne Michaux
MDMichel Delforge
Michel Delforge
Background: Light-chain amyloidosis has always been described as a sporadic disease caused by plasma cell dyscrasia. Cardiac amyloidosis refers to cardiac involvement with infiltration of amyloid fibrils in the myocardium. The degree of cardiac involvement is the greatest predictor of prognosis. To our knowledge, AL cardiac amyloidosis has only been reported once before in first-degree relatives. Case summary: In this report, we describe the unusual cases of two sisters with light-chain cardiac amyloidosis. The first patient underwent autologous stem cell transplantation and remained in remission for 10 years until the disease relapsed and she died of end-stage heart failure. The second patient was promptly started on a chemotherapy regimen but died shortly after her initial diagnosis due to rapid progression of cardiac dysfunction. Conclusion: Cardiac amyloidosis is a severe life-threatening condition which requires a multidisciplinary diagnostic and therapeutic approach. Based on this case report, a genetic cause for AL amyloidosis might be suspected or is this a purely coincidental finding? Counselling, screening, and follow-up of other family members are very challenging. As is often the case with rare diseases, many unsolved questions remain, representing important challenges for clinicians.

28 March 2023 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
BDBirgit Decommer
Birgit Decommer
MVMatthias Verbesselt
Matthias Verbesselt
EWErik Wouters
Erik Wouters
JSJerrold Spapen
Jerrold Spapen
GCGuy Van Camp
Guy Van Camp
A 78-year-old woman, known with type 2 diabetes and paroxysmal atrial fibrillation, presented with fatigue, weight loss, and confusion. There was no fever, but physical examination revealed extensive petechiae and a loud systolic and diastolic heart murmur. Lab results showed acute kidney failure (creatinine 2.64 mg/dL) and mild inflammation [C-reactive protein (CRP) 26.8 mg/L]. Coagulation tests were found to be abnormal with elevated D-dimers (>7000 µg/L), international normalized ratio (INR) of 3.8, and marked thrombocytopaenia (41.000/µL) suggesting disseminated intravascular coagulation. Due to deteriorating neurological status, a computed tomography (CT) scan of the brain was performed which showed diffuse ischaemic lesions suspicious for a cardioembolic source. Transoesophageal echocardiography demonstrated very thick non-mobile vegetations on the aortic valve, causing severe valvular regurgitation ( Figure 1A–C). The leaflets of the mitral valve were also thickened with the presence of mobile structures on the atrial side, highly suggestive of endocarditis ( Figure 1A). Repeated blood cultures were negative.

1 April 2023 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
MVMatthias Verbesselt
Matthias Verbesselt
BJBogaert Jan
Bogaert Jan
TCThomas Castelein
Thomas Castelein
BSBernard Stockman
Bernard Stockman
BMBart Meyns
Bart Meyns
CVChristophe Vandenbriele
Christophe Vandenbriele
A 39-year-old male patient, known with morbid obesity [body mass index (BMI) 45 kg/m²], was referred with progressive shortness of breath over the last 2 years. He reported acute worsening over the past 3 weeks and malleolar oedema and haemoptysis over the past 3 days. No fever was recorded. Electrocardiogram showed sinus tachycardia with SIQIIITIII sign, and troponins (78 ng/L, reference < 14 ng/L), D-dimers (>4400 µg/L, reference < 550 µg/L), N-terminal pronatriuretic peptide (8370 ng/L, reference < 125 ng/L), and lactate levels (9.1 mmol/L) were markedly elevated. COVID polymerase chain reaction (PCR) on admission was positive (3–5 log copies). Pulmonary computed tomography (CT) showed bilateral embolism in segmental pulmonary arteries with accompanying infarctions. Furthermore, intracardiac biventricular masses were noted, which were identified as intraventricular thrombi on cardiac ultrasound due to low flow (Panels A and B). The left and right ventricles were largely dilated [left ventricular end-diastolic diameter (LVEDD) 7.5 cm] with severely impaired systolic function [left ventricular ejection fraction (LVEF) 11%; right ventricular ejection fraction (RVEF) 12%]. On cardiac magnetic resonance imaging (MRI), T1 and T2 values and extracellular volume were elevated, suggesting either myocardial oedema or inflammation. There was no focal late gadolinium enhancement (LGE) (Panels C and D showing cine images, Panels E and F showing LGE images; see Supplementary material online , Videos S1–S4). The patient was admitted to the cardiac intensive care unit because of rapid progression to stage D cardiogenic shock according to the Society for Cardiovascular Angiography and Interventions (SCAI) score and was promptly started on therapeutic unfractionated heparin infusion, inotropes (milrinone), and intravenous diuretics. After 11 days of highly intensive medical treatment, including administration of levosimendan and achieving 10 L of fluid loss, the patient remained in refractory cardiogenic shock (SCAI-C), still requiring high doses of inotropes. The case was discussed in the multidisciplinary heart team, and a left ventricular assist device (LVAD) was implanted as a ‘Bridge-to-Decision’ strategy with resection of the left ventricular (LV) thrombus (Panel G: LV thrombus surgical specimen, Panel H: postoperative CT). Postoperatively, he had a rapid recovery, and vitamin K antagonists, as standard therapy in LVAD-supported patients, were initiated as long-term anticoagulation therapy. Three weeks after surgery, the patient was discharged home. Six months after discharge, he is doing quite well and his weight has dropped to a BMI of 34 kg/m². Ahead of a heart transplant, additional bariatric surgery will presumably be provided before active listing.

20 October 2023 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
MVMatthias Verbesselt
Matthias Verbesselt
BDBirgit Decommer
Birgit Decommer
DSDan Schelfaut
Dan Schelfaut
FCFilip Casselman
Filip Casselman
FPFrank Van Praet
Frank Van Praet
GCGuy Van Camp
Guy Van Camp
Matthias Verbesselt, Birgit Decommer, Dan Schelfaut, Filip Casselman, Frank Van Praet, Guy Van Camp; Recurrent patch dehiscence of left ventricular aneurysm, an

17 May 2023 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
MVMatthias Verbesselt
Matthias Verbesselt
BBBernard De Bruyne
Bernard De Bruyne